Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021
14 April 2021 - 9:00PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or transection
to peripheral nerves, today announced that it will report first
quarter 2021 financial results on Wednesday, May 5, 2021 after the
market closes. Axogen management will host an investment-community
conference call and webcast following the release at 4:30 p.m. ET.
Investors interested in participating in the conference call by
phone may do so by dialing toll free at (877) 407-0993 or use the
direct dial-in number at (201) 689-8795. Those interested in
listening to the conference call live via the Internet may do so by
visiting the Investors page of the company's website
at www.axogeninc.com and clicking on the
webcast link.
Following the conference call, a replay will be available in the
Investors section of the company's website at
www.axogeninc.com.
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard Nerve Connector®,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
Nerve Cap®, a porcine submucosa ECM product used to protect a
peripheral nerve end and separate the nerve from the surrounding
environment to reduce the development of symptomatic or painful
neuroma; and Avive® Soft Tissue Membrane, a processed human
umbilical cord intended for surgical use as a resorbable soft
tissue barrier. The Axogen portfolio of products is available in
the United States, Canada, the United Kingdom, South Korea, and
several other European and international countries.
Contact:Axogen, Inc.Peter Mariani, Executive Vice
President and Chief Financial
OfficerInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2024 to May 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From May 2023 to May 2024